OTCM
AMBFF
Market cap2.68bUSD
, Last price
Name
Ambu A/S
Chart & performance
P/E
—
P/S
—
EPS
2.62
Vol. 1Y
—
Shs. 5Y
1.49%
Rev. 5Y
11.10%
Div Yld LY
—
Div Yld TTM
—
Revenues
6.04b
+11.98%
Net income
609m
+159.15%
CFO
791m
-2.71%
Dividend
Dec 05, 20250.0639 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics segmet provides electrodes for cardiology, neurophysiology, and polysomnography. The Visualisation segment includes single-use visualisation devices, which are used in single lung ventilation procedure, or a bedside bronchoscopy procedure in the intensive care unit . The company was founded by Holger Hesse in 1937 and is headquartered in Ballerup, Denmark.
Key people
Joergen Jensen
Independent Chairman of the Board · since 2020
Britt Jensen
Chief Executive Officer, Member of the Executive Board · since 2022
Shacey Petrovic
Independent Vice Chairman of the Board · since 2023
Scott Heinzelman
President, North America · since 2025
Graziela Malucelli
Chief Operations Officer · since 2024
Sanne Hjordrup
Chief People Officer · since 2025
Finn Mohring
Chief Technology Officer · since 2025
Bassel Rifai
President of EMEA and APAC · since 2025
Jesper Steen
Chief Marketing Officer · since 2025
Henrik Bender
Chief Financial Officer, Member of the Executive Board · since 2024
Jesper Mads Bartroff Frederiksen
Director, Employee Representative · since 2021
Charlotte Bjoernhof
Director, Employee Representative · since 2021
Thomas Jensen
Director, Employee Representative · since 2021
Independent Director · since 2021
David Hale
Independent Director · since 2024
Simon Hoffmann
Independent Director · since 2022
Susanne Larsson
Independent Director · since 2021
Headquarters & legal address
Baltorpbakken 13
Ballerup, 84 2750
DK
Ballerup, 84 2750
DK
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||